




# Achieving Equilibrium in ESRD Patients

- Marc Richards MD
- South Florida Kidney Disease and HTN Specialists
- Chief of Medicine, BRRH
- BRRH Grand Rounds: April 18<sup>th</sup>, 2017

# Outline

- Dialysis prescription
- Adequacy
- Estimated Dry Weight (EDW)
- Electrolytes / Acid-Base
- Anemia
- Bone Mineral Disease (BMD)

# DIALYSIS Rx



# Dialysis Adequacy

- Effective removal of uremic solutes
  - Small, water soluble
    - Urea “BUN”
  - Small, protein bound
    - Indoles
    - Phenols
  - Middle molecules
    - B2 microglobulin
- **Note:** “adequate dialysis”  $\neq$  “doing well on dialysis”

# BUN



- Advantages

- Easily measurable- index of nitrogenous waste products from protein consumption

- Disadvantages

- Studies suggest difficult to measure uremic solutes may be more important
- BUN can be different than expected due to different clinical states

# Urea Reduction Ratio (URR)


$$URR = \frac{U_{pre} - U_{post}}{U_{pre}} \times 100\%$$

- Simple
- Goal: 65% or more
- Doesn't take into account urea generation or UF

## Kt/V = Fractional Urea Clearance

- **K** = dialyzer clearance of urea (mL/min)
- **t** = time of dialysis tx (min)
- **V** = volume of distribution (mL) = TBW
- **WARNING**: gory math details ahead!
- HD pt- mass **70 kg** (154 lb) , HD **t=4 hours**, dialyzer urea clearance **215 ml/min**.
- $Kt/V = [215 \times 240] / [70000 \times 0.6] = 1.23$

# Correlation b/t URR and $Kt/V$






# Limitations

- Can be artificially elevated by an elevated “Kt” or a diminished “V”
- Assumes urea removal is similar to other uremic toxins/ middle molecules
- BUN “rebound”

# So if decent $Kt/V$ is good, is a lot more even better?

- HEMO TRIAL (NEJM 2002)
- $Kt/V$ 
  - 1.32 (SD)
  - 1.71 (HD)
  - RR 0.96



# How to manage inadequate $Kt/V$

- \*More time
- Bigger dialyzer (higher flux)
- Increase BFR
  - AVF/AVG instead of CVC
  - Larger gauge needles
- Ensure no recirculation
- Preserve RRF


# Fluid/Volume Balance



- Patients weighed at beginning (**B**) and end (**E**) of each treatment
- **B**→**E**: UF (Liters) = Weight lost (kg)
  - Parameter we set, usually aiming for **EDW**
- **E**→**B**: Interdialytic weight gain (IDWG)
  - Driven by patient **salt** > **fluid** intake


# High IDWVG is bad → High UFR

- Major dialysis orgs advise max rate 13mL/h/kg



# Overaggressive clearance can be harmful, too.

## Water movement during standard hemodialysis



# Consequences of over/underaggressive ultrafiltration

Too much UF (*<EDW)	Too little UF (>EDW)
Syncope	Volume Overload
Presyncope	Hypertension
Chest Pain	Edema
Cramping	CHF
Hypotension	LVH
General organ hypoperfusion	

\*Patients can be simultaneously volume overloaded and overaggressively ultrafiltrated!


# Estimated Dry Weight (EDW)

- Rough definition: Normal seated BP at end of HD treatment without orthostatic hypotension or signs of volume overload
- Difficult to measure
- Relies on clinical judgment / “trial and error”
- Multiple alternative techniques being developed



# CritLine



- Cuvette attached to dialyzer estimates hematocrit
- Hematocrit increases with removal of blood volume
- Slope of curve  $>5\%$  suggests overaggressive UF



# Bioimpedence

- Onofriescu, AJKD 2014
- Mortality HR 0.112
- Less BP meds in BI group

Mean relative fluid overload



# Other Methods

- Plasma ANP


- More elevated in hypertensive pts predialysis
- Lower at end of HD if BP was dialysis-sensitive
- Absolute values not helpful to predict EDW

- IVC Diameter

- “standardized” measurements postdialysis often included many hypertensive or overloaded pts

# Dialysis Clearance


- **DIFFUSION**
  - Higher  $\rightarrow$  lower concentrations
  - Bidirectional
- **CONVECTION**
  - Solvent drag
  - Effective for middle molecules



# Dialysate Composition


Electrolyte	Concentration (meq/liter)
Sodium	134-140
Potassium	0-4
Bicarbonate	34-40
Calcium	2-3 (1 meq/L = 4 mg/dL)

# Dialysate Sodium



Sodium level at  
start of HD  
(n=1084)


Sodium gradient  
= D.Na - S.Na



Higher Na  
gradient →  
higher  
IDWG


# Dialysate Sodium

Implications of current trends toward prescribing high dialysate sodium in HD



# Dialysate Potassium


- Generally 2-3meq/L
- Emergently can use 0K bath
  - Need to check frequent blood gas Ks
  - Not available at BRRH





# Dialysate Potassium

- Predialysis hyperkalemia
- Postdialysis hypokalemia
- →SCD?



**Figure 2 | Ratio of actual to expected number of occurrences of sudden death for each 12 h interval beginning with the start of HD.**

# Dialysate Bicarbonate

- Primary buffer
- 34-40meq/L
- Pts mildly acidotic at start of tx




Image taken from Nursing Consultants, Inc.  
<http://www.nursinged.com/index.html>

# Dialysate Calcium

- 2-3 meq/L (usually 2.5meq/L)
- **Low Ca** baths associated with increased risk of hypotension
  - Decreased cardiac contractility
- **High Ca** baths can calcium load
  - Caution with binder, vitamin D use!
  - Increased [Ca x P]
  - May be needed following parathyroidectomy

# Anemia in ESRD

- Kidneys produce 90% of circulating EPO
- EPO production declines as CKD advances
- Less EPO → apoptosis of erythroid cell progenitors
- Iron deficiency

# Clinical Manifestations

- Fatigue
- Cognitive impairment
- Decreased libido
- Decreased exercise tolerance
- DOE
- Increased CV risk

# Iron Deficiency



- Causes
  - Decreased GI absorption
  - Occult GIB
  - Phlebotomy
  - Dialysis effects
  - ESAs exhaust iron stores
- Indications to treat:  $T_{sat} < 20-30\%$ , HgB variable


# Erythropoetin Stimulating Agents (ESAs)

- Epogen/Procrit
- Darbopoetin/Aranesp
  
- SC or IV\* administration
- Goal HgB ~ 10-11 g/dL
  
- Benefits
  - Improved M&M
  - Less transfusions
  - Improved QOL and exercise tolerance

# Target HgB

- CHOIR Trial (NEJM 2006)
- ~1400 CKD (non HD) pts
- Goal HgB  
11.3 vs 13.5


A



No. of Patients

High-hemoglobin	710	667	632	600	558	507	485	433	367	306	252	194	139	95	81	67	49	31	13
Low-hemoglobin	707	672	625	603	549	528	510	471	384	334	250	182	141	101	75	60	45	30	13

B



No. of Patients


High-hemoglobin	709	693	659	623	578	530	500	452	370	310	258	189	132	97	79	65	52	27	11
Low-hemoglobin	707	691	655	621	577	549	526	479	393	333	262	189	141	95	73	54	43	27	12



# CHOIR Trial: Results

- Composite endpoint- death, myocardial infarction, hospitalization for congestive heart failure without renal replacement therapy, or stroke

A Primary Composite End Point




**No. at Risk**

High-hemoglobin	715	654	587	520	457	355	270	176	101	72	55	23
Low-hemoglobin	717	660	594	539	499	397	293	182	107	67	44	23

# What about HD patients?

- Normal Hematocrit Trial (NHT)- 1998
- All patients with heart disease (CHF, CAD)
- Stopped early



No. AT RISK


Normal hematocrit	618	540	476	415	353	259	186	124	69	26
Low hematocrit	615	537	485	434	391	292	216	131	80	20

# ESA Adverse Effects


- When aiming for normal HgB
  - Increased mortality
  - CV events
  - Malignancy
  - Access thrombosis
    - NHT 39% vs 29% in normal HgB group
- When aiming for any HgB
  - Hypertension
    - Vasoconstriction – EPO receptors in blood vessels

# CKD-MBD


- nkf




# Mechanism...



# Mechanism...



# Treatment



- Very difficult
- Medications will simultaneously improve and worsen various lab values
- Goals:
  - Ca 8.5-10.2
  - Ph 3.5-5.5
  - $[Ca \times P] < 55$
  - PTH  $< 500-600$
  - VitD  $> 30$





# Medication Options

	Calcium	Phosphorous	PTH
<b>Phos Binders (calcium based)</b>	↑	↓	↓ ↔
<b>Phos Binders (non calcium based)</b>	↔	↓	↓ ↔
<b>Activated Vitamin D</b>	↑	↑	↓
<b>Cinacalcet</b>	↓	↓	↓

\*In addition to low phos diet!



# Summary

- ESRD patients suffer from a large number of hemodynamic, chemical, hematologic, and musculoskeletal abnormalities.
- Optimization of the dialysis prescription can help mitigate many of these issues

# Thank You!

- Dr Ira Lazar, Dr John Panos, Dr Eric Lazar, and/or myself are always around to answer questions and be of assistance.
- Email: [marc.richards@gmail.com](mailto:marc.richards@gmail.com)
- Cute picture of kids:

